Month: September 2022

EDISON, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that its research collaborators from London’s Institute of Hepatology will present new findings on the Company’s cyclophilin inhibitor, rencofilstat, in an awarded oral presentation at the 2022 joint meeting of the International Society for Biomedical Research on Alcoholism (ISBRA) and European Society for Biomedical Research on Alcoholism (ESBRA), taking place September 17-20, 2022 in Cracow, Poland. Alcohol-associated liver disease (“ALD”) is a global health burden with a lack...

All Merger-related proposals approved at the Annual Meeting of Stockholders BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held September 13, 2022, its stockholders approved all of the merger-related proposals, including: (i) the Agreement and Plan of Merger and Reorganization, dated as of April 26, 2022, by and among Caladrius and Cend Therapeutics (“Cend”), and the transactions contemplated thereby, including the Merger and the issuance of shares of Caladrius’ common stock to Cend’s stockholders pursuant to the Agreement and Plan of Merger and Reorganization, (ii) an amendment to the amended and restated...

– Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 – – Drug levels achieved with sub-cutaneous formulation equivalent to IV formulation – SAN DIEGO and REDWOOD CITY, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has dosed the first patient in the second cohort of its Phase 1b clinical trial of zotatifin in non-hospitalized adults with confirmed COVID-19 infection. The study is a double-blind, randomized, placebo-controlled trial evaluating the safety and antiviral activity of a single dose of zotatifin and is being conducted in collaboration with the Quantitative...

Tel Aviv, Israel, Sept. 14, 2022 (GLOBE NEWSWIRE) — Arbe Robotics Ltd. (Nasdaq: ARBE) (“Arbe”), the global leader in next-generation 4D Imaging Radar solutions, today announced that Kobi Marenko, Chief Executive Officer, and Karine Pinto-Flomenboim, Chief Financial Officer, will be participating at the Jefferies Israel Tech Trek 2022 in Tel Aviv on Wednesday, September 21 at The David Kempinski Hotel. The company will hold one-on-one investor meetings during the day. Please contact your Jefferies salesperson to schedule a meeting. For more information regarding this event, please visit Arbe’s events page here. About Arbe Arbe (Nasdaq: ARBE), the global leader in Perception Radar Chipset Solutions, is spearheading a revolution in sensing, enabling truly safe driver-assist systems today while paving the way to full autonomous-driving....

MADRID, Spain and WALL, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB), today announced that Swivel Secure Europe today deployed AuthControl Sentry to a Dutch-based multinational conglomerate (“Company”) in the furniture and home accessories market that will allow their suppliers to have secure SSO access to legacy enterprise applications. For the Company, its suppliers and service providers are its most important partners for maintaining vital business operations and supply chain logistics, so ensuring seamless, secure access to key applications and data is mission critical for their business. The BIO-key solution assisted the Company with implementing...

Photos 1 and 2: Photo 1 (left): Disseminated pyrite within a diorite unit outcropping along the highway. Assays returned values up to 8.2 g/t Au and 130 g/t Ag. Photo 2 (right): Limonitic felsic intrusive float with up to 10% pyrite. This unit is found as float within a 400x300m boulder field. Assays from the felsic rock returned values up to 5.6 g/t Au and 30.7 g/t Ag.Figure 1: Eakin Creek property IP and geochemical results. Resistivity and chargeability at 50m (left) and gold in soil (right) with overlaid rock grab sample.VANCOUVER, British Columbia, Sept. 14, 2022 (GLOBE NEWSWIRE) — Trailbreaker Resources Ltd. (TBK.V) (“Trailbreaker” or “the Company”) is pleased to announce the results of the Phase 1 exploration program at its 100%-owned Eakin Creek property in south-central British Columbia (BC). A 1,000 x 600-metre...

– New preclinical data indicate IL-27 induces a gene expression signature that has been associated with resistance to chemotherapy, radiotherapy, and checkpoint inhibition – – Findings support the ongoing clinical investigation of SRF388 in multiple tumor types – CAMBRIDGE, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company will present new preclinical data on the role of IL-27 in therapy resistance at the 10th Annual Cytokines Meeting of the International Cytokine and Interferon Society (ICIS) being held September 20 – 23 at Big Island, Hawaii. The poster, entitled IL-27 Inhibits Immune Cell Reinvigoration Mediated by PD-(L)1...